证券代码：688013 证券简称：天臣医疗 公告编号：2026-004 天臣国际医疗科技股份有限公司 关于审计机构变更项目质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 天臣国际医疗科技股份有限公司（以下简称"公司"）于2025年8月26日召 开第二届董事会第二十八次会议，于2025年9月12日召开2025年第三次临时股东 会，审议通过《关于公司续聘2025年度审计机构的议案》，同意公司续聘公证天 业会计师事务所（特殊普通合伙）（以下简称"公证天业"）为公司2025年度审 计 机 构 ， 具 体 内 容 详 见 公 司 于 2025 年 8 月 27 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《关于公司续聘2025年度审计机构的公告》（公告编 号：2025-049）。 公司于近日收到公证天业通知，因原项目质量控制复核人工作调整，变更了 项目质量控制复核人。现将具体情况公告如下： 2、诚信记录 姜铭近三年不存在因执业行为受到刑事处罚，受到证监会及其派出机构、行 1 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2026-003 天臣国际医疗科技股份有限公司 关于董事会完成换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科 创板上市公司自律监管指引第1号——规范运作》等法律、法规、规范性文件及 《天臣国际医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，天臣国际医疗科技股份有限公司（以下简称"公司"或"天臣医疗"）于2026年 1月7日召开2026年第一次临时股东会，选举产生了3名非独立董事和3名独立董事， 与公司通过职工代表大会选举产生的1名职工代表董事，共同组成公司第三届董 事会。 同日，公司召开第三届董事会第一次会议，选举产生董事长、董事会各专门 委员会委员及主任委员（召集人），并聘任高级管理人员及证券事务代表。现将 相关情况公告如下： 一、董事会换届选举情况 （一） ...

一、 会议召开和出席情况 证券代码：688013 证券简称：天臣医疗 公告编号：2026-002 天臣国际医疗科技股份有限公司 2026年第一次临时股东会决议公告 （一） 股东会召开的时间：2026 年 1 月 7 日 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （二） 股东会召开的地点：苏州工业园区东平街 278 号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 20 | | --- | --- | | 普通股股东人数 | 20 | | 2、出席会议的股东所持有的表决权数量 | 42,346,654 | | 普通股股东所持有表决权数量 | 42,346,654 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.6072 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.6072 | （四） 表决方式是否符合《 ...

国浩律师（上海）事务所 关 于 天臣国际医疗科技股份有限公司 2026 年第一次临时股东会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 在审查有关文件的过程中，公司向本所律师保证并承诺，其向本所提供的文 件和所作的说明是真实的，有关副本材料或复印件与原件一致。 公司向本所律师保证并承诺，公司已将全部事实向本所披露，无任何隐瞒、 遗漏、虚假或误导之处。 二零二六年一月 国浩律师（上海）事务所 关于天臣国际医疗科技股份有限公司 2026 年第一次临时股东会之 法律意见书 致：天臣国际医疗科技股份有限公司 天臣国际医疗科技股份有限公司（以下简称"公司"）2026 年第一次临时股 东会于 2026 年 1 月 7 日召 ...

Core Insights - Tianchen Medical (688013) closed at 51.22 yuan on January 5, 2026, with a 6.53% increase and a turnover rate of 3.26% [1] - The company reported a net outflow of 1.708 million yuan from main funds, while retail investors saw a net inflow of 597,400 yuan [1] Financial Performance - For the first three quarters of 2025, Tianchen Medical achieved a main revenue of 244 million yuan, a year-on-year increase of 20.66% [3] - The net profit attributable to shareholders reached 71.9458 million yuan, up 68.29% year-on-year, with a non-recurring net profit of 66.2023 million yuan, increasing by 71.85% [3] - In Q3 2025, the company reported a quarterly main revenue of 87.6631 million yuan, a 26.4% year-on-year increase, and a quarterly net profit of 23.7342 million yuan, up 70.74% [3] - The company's debt ratio stands at 11.3%, with an investment income of 2.556 million yuan and financial expenses of -10.8703 million yuan, resulting in a gross profit margin of 63.22% [3] Financing and Margin Information - On January 5, 2026, Tianchen Medical had a financing buy of 10.4463 million yuan and a financing repayment of 14.4032 million yuan, resulting in a net repayment of 3.9569 million yuan [2] - The company has a financing and margin balance of 2.12 billion yuan [2]

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

Group 1 - Maduro denies all charges from the U.S. and claims he is still the President of Venezuela [2] - The U.S. has accused Maduro of drug terrorism conspiracy, cocaine smuggling conspiracy, and possession of firearms [2] - Maduro states he was forcibly taken from his home in Caracas [2] Group 2 - China condemns the U.S. for violating Venezuela's sovereignty and international principles [3] - The U.S. is accused of undermining multilateralism and threatening peace in Latin America and the Caribbean [3] Group 3 - Venezuela's oil exports have nearly dropped to zero due to U.S. sanctions and blockade [4] - The Venezuelan oil company is reducing production and closing some oil fields due to accumulated inventory [4] - Shortages of diluents for blending heavy crude oil are further restricting production activities [4] Group 4 - Trump claims the U.S. must have complete access to Venezuela's resources and asserts U.S. control over the country [5][6] - The U.S. Vice President's residence was attacked, with one suspect arrested [6] Group 5 - High expectations for Chinese stocks with projected annual growth of 15% to 20% in 2026 and 2027 [8] - Corporate earnings in China are expected to grow by 14% and 12% in 2026 and 2027, respectively [8] - Factors driving growth include AI applications, international expansion, and policies to reduce internal competition [8]

Core Viewpoint - The announcement details the signing of a strategic cooperation agreement between Tianchen Medical and Inspur Digital Technology (Shanghai) Co., Ltd, aimed at promoting innovation and industrialization in medical intelligence and information technology [2][3]. Group 1: Agreement Overview - The strategic cooperation agreement is a framework agreement that does not specify any financial commitments, with specific cooperation details to be defined in future contracts [2][3]. - The agreement was signed on December 31, 2025, in Shanghai, and does not require board or shareholder approval as it is an intention-based agreement [4][12]. - The agreement establishes a partnership to leverage both companies' resources to advance medical intelligence and information technology in medical device manufacturing and medical robotics [3][12]. Group 2: Cooperation Details - The cooperation will focus on several areas, including: - Medical intelligence and information technology, where Inspur will provide digital solutions for Tianchen's smart factory design and supply chain management [5][12]. - Joint research and development in medical robotics, combining Inspur's technology with Tianchen's expertise in medical devices [5][12]. - Market collaboration and brand building, where both companies will prioritize each other's products and services and participate in joint promotional activities [6][7]. Group 3: Impact on Company - The signing of the agreement is a significant step in implementing the company's dual-engine strategy, which focuses on minimally invasive capabilities and intelligent surgical robotics [12]. - The agreement is expected to provide a framework for future project cooperation, facilitating industrial integration and mutual benefits without affecting the company's main business or independence [12].

Group 1 - Fulin Precision's subsidiary plans to invest 6 billion yuan to build a high-end lithium iron phosphate project with an annual production capacity of 500,000 tons [11] - Feiwo Technology has completed the acquisition of 60% of Xinsai Aerospace, focusing on metal 3D printing services for commercial aerospace [2] - Zhongcai Technology expects a net profit increase of 73.79% to 118.64% in 2025 [30] Group 2 - Hengrui Medicine has received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity [2] - Deyun Co. announced that its actual controller has been arrested for illegal public deposit collection, but the company's operations remain normal [3] - Hengshi Technology's control is set to change as it enters a strategic cooperation agreement with New Base Information Technology Group [4] Group 3 - Zhejiang Mining plans to acquire 100% of Alaigyr Company, which holds core assets in lead-silver mines [5][6] - Guizhou Tire intends to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [7] - Dongfang Zircon plans to invest in a project to produce 10,000 tons of high-purity composite zircon oxide for new energy batteries [8] Group 4 - Xingsheng Group has received a project designation notice from a North American electric vehicle manufacturer, with a total sales amount of approximately 7.8 billion yuan [18] - Jin Di Co. plans to acquire a 3.36% stake in Baoshilai New Materials Technology for 21.6 million yuan [10] - Huayi Technology has signed a strategic cooperation agreement with Fujian Fuyou University to enhance research and development in alloy materials [6] Group 5 - Juxing Technology expects a net profit increase of 5% to 20% in 2025 [23] - Huayou Cobalt anticipates a net profit increase of 40.8% to 55.24% in 2025 [24] - Chifeng Gold expects a net profit increase of approximately 70% to 81% in 2025 [25]

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]